Insulin resistance modulation

Insulin resistance modulation is a therapeutic and physiological process aimed at restoring the cellular response to insulin, primarily in peripheral tissues such as skeletal muscle, the liver, and adipose tissue (StatPearls, 2023). It is not a single molecular target or receptor but rather a phenotypic outcome achieved through the coordination of various signaling pathways that regulate glucose and lipid metabolism (NIH, 2022). In the state of insulin resistance, which is central to Type 2 diabetes and metabolic syndrome, the insulin signaling cascade is typically inhibited by factors such as chronic inflammation, excessive lipid accumulation, and oxidative stress (PubMed: Wilcox, 2005). Drugs that modulate this state, known as insulin sensitizers, act on diverse molecular targets like the Peroxisome proliferator-activated receptor gamma (PPAR-gamma), AMP-activated protein kinase (AMPK), and the Insulin receptor (INSR) (Nature Reviews Drug Discovery, 2021). These interventions work to increase the translocation of glucose transporters like GLUT4 to the cell membrane and suppress excessive glucose production by the liver (Journal of Clinical Investigation, 2013). Because 'Insulin resistance modulation' describes a broad pharmacological strategy involving multiple discrete proteins and biological systems rather than a specific biological entity, it is categorized as a physiological process or therapeutic category.

Other names

Insulin sensitizationImprovement of insulin sensitivityReduction of insulin resistanceMetabolic sensitization

Modulation is achieved through several distinct pathways: 1) Activation of Peroxisome proliferator-activated receptor gamma (PPAR-gamma) by thiazolidinediones to improve adipocyte function and gene expression related to glucose/lipid metabolism (Journal of Clinical Investigation, 2013); 2) Activation of AMP-activated protein kinase (AMPK) by biguanides like metformin to reduce hepatic gluconeogenesis and increase muscle glucose uptake (NIH, 2022); and 3) Potential inhibition of Protein-tyrosine phosphatase 1B (PTP1B) to prolong insulin receptor phosphorylation and downstream signaling (Wilcox, 2005).